Effectiveness of Task Specific Home Exercise Program
Part of paid clinical trials in Brooklyn, New York.
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
- Study ID
- NCT06486116
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Interventions
- Task Specific Physical Therapy Home Program — BEHAVIORALHome exercise program based on specific findings from physical therapy evaluations.
Study Details
The purpose of this study is to compare the effectiveness of 2 different types of Home Exercise Programs (HEP) on mobility in persons with Multiple Sclerosis (MS). Specifically, we will be comparing the Standard of Care (SOC) a program based on aerobic conditioning and calisthenics to a Task Specific Program (TSP). Primary Question: Will persons with who receive a Task Specific HEP have greater improvement in mobility than those who receive the SOC? Secondary question: Will a task specific HEP be as well tolerated as the SOC HEP by persons with MS
Key Dates
- Start date
- Jun 1, 2024
- Status verified
- Jun 2024
- Primary completion
- Dec 31, 2025
- Completion
- Jan 31, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Individualized Task Specific Physical Therapy Home Exercise ProgramPhysical Therapy Home Exercise program based on specific outcome measure findings.
- Active Comparator: Generic physical therapy home exercise programGeneralized fitness-based exercise program
Primary Outcome Measure
6 Minute Walk Test [ Time Frame: Measured before and after each 4 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| New York Presbyterian Brooklyn Methodist Hospital | Brooklyn | New York | 11215 | Karen Blitz-Shabbir, DO (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Brooklyn, NY
By condition
By specialty
By research site
Related Studies
- Genes and Environment in Multiple SclerosisRecruiting · Columbia University · Bethesda, Maryland
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut
- Vancomycin Study in Multiple Sclerosis (MS)PHASE1 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York